Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib versus placebo as adjuvant therapy for completely resected stage IIB/C BRAF V600E/K melanoma
MOH_2022-09-15_012055Phase 3Not yet recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in cutaneous melanoma (CM) comparing Encorafenib + binimetinib with Matching placebo (2 arms). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on MOH_2022-09-15_012055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-15_012055.